Dec 04, 2021 Health

Have learn about the vitro fertilization

The gold standard for evaluating these parameters in a woman’s ovaries, however, is missing. And for any available measure of ovarian reserve there is no universally accepted clinical cut-off value (i.e., the optimal minimum) . Precisely in this void fits the new Access Anti-Müllerian Hormone (AMH) Advanced test , recently launched by Beckman Coulter , a world leader in infertility diagnostics and testing iui singapore.

“Offering all medical professionals a valuable tool that supports the delicate path of medically assisted procreation is our primary goal. In fact, we believe that the success of the therapy depends on its personalization and its constant monitoring. The availability of this new test makes us proud to be a daily partner of laboratory medicine.

The test, in fact, allows to avoid overstimulation of the ovaries because it helps to establish the individual daily dose of the human recombinant follicle stimulating hormone rFSH.

What is AMH?

The anti-Müllerian hormone (AMH) in women is produced by the granulosa cells of the preantral and small antral ovarian follicle from the age of development until the menopause. Le its concentrations reflect the number of follicles small at the beginning of the growth phase, and are then indicative  of the number of primordial follicles remaining still in the ovary, namely the famous ovarian reserve . The AMH levels decrease during the reproductive life of the woman and reflect the progressive decline of the amount determined from the age of oocytes and the associated ovarian aging.

On the side of women

For all these reasons, AMH is a widely used biomarker in the evaluation of female clinical conditions . These include infertility, in fact, but also menopause, ovarian dysfunction (such as polycystic ovary syndrome), gonadal cancer and ovarian surgery. Consequently, the AHM test becomes a valuable tool in monitoring women’s health.